FMTX - Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation

Forma Therapeutics ([[FMTX]] +2.9%) gains while competitor Agios Pharmaceuticals slides, after the pair presented updated data for their sickle cell disease candidates at the annual ASH meeting.FMTX’s FT-4202 data suggest a best-in-class asset as hemoglobin response rate was higher than both competitors Agios’s mitapivat and Global Blood’s Oxbryta, wrote SVB Leerink analyst, Andrew Berens. He also mentioned that FT-4202 didn’t demonstrate any additional cardiac events or induce self-metabolism as was seen with AGIO’s drug.Hemolytic markers support hypothesis that FT-4202 improves red blood cell survival and reduces turnover. 6/7 patients on 300mg of FT-4202 for 14 days achieved a hemoglobin increase of more than 1 g/dL from baseline.Favorable tolerability profile was observed after once-daily dosing of FT-4202 for 14 days and 7- day follow-up period.

For further details see:

Forma Therapeutics' sickle cell treatment shows promising action at ASH presentation